Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last C$0.05 CAD
Change Today 0.00 / 0.00%
Volume 0.0
MFS On Other Exchanges
Symbol
Exchange
Venture
OTC US
Frankfurt
As of 11:58 AM 09/2/15 All times are local (Market data is delayed by at least 15 minutes).

medifocus inc (MFS) Snapshot

Open
C$0.06
Previous Close
C$0.05
Day High
C$0.06
Day Low
C$0.05
52 Week High
05/29/15 - C$0.16
52 Week Low
03/25/15 - C$0.04
Market Cap
7.5M
Average Volume 10 Days
4.5K
EPS TTM
C$-0.05
Shares Outstanding
166.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for MEDIFOCUS INC (MFS)

Related News

No related news articles were found.

medifocus inc (MFS) Related Businessweek News

No Related Businessweek News Found

medifocus inc (MFS) Details

Medifocus Inc., a medical technology company, develops and commercializes minimally invasive focused heat systems for the treatment of cancerous and benign tumors, and enlarged prostate in Canada. It owns technology platforms, including Endo-thermotherapy platform, a catheter-basis focused heat technology platform that utilizes natural body openings to deliver precise microwave thermotherapy to the diseased sites; and Adaptive Phased Array Microwave Focusing platform, which directs precisely focused microwave energy at tumor center to induce shrinkage or eradication of tumors without undue harm to surrounding tissue. The company offers Prolieve thermodilatation system, a medical device based on endo-thermotherapy for the treatment of benign prostatic hyperplasia. It is also developing APA 1000, a breast cancer treatment system, which is in pivotal Phase-III clinical trials. Medifocus Inc. is based in Toronto, Canada.

medifocus inc (MFS) Top Compensated Officers

Founder, Chairman of The Board, Chief Executi...
Total Annual Compensation: C$215.3K
Chief Financial Officer and Director
Total Annual Compensation: C$75.0K
Chief Operating Officer
Total Annual Compensation: C$203.8K
Compensation as of Fiscal Year 2015.

medifocus inc (MFS) Key Developments

Medifocus Inc. Appoints Christopher Kaplan as Member of Strategic Advisory Board (SAB)

Medifocus Inc. announced that the company has appointed Christopher Kaplan as a member of the its recently formed Strategic Advisory Board (SAB). Mr. Kaplan is currently President of Cajetan, LLC. Prior to Cajetan, Mr. Kaplan spent two years with Boehringer Ingelheim as Senior Vice President and Chief Marketing Officer.

Medifocus Inc. Appoints Joseph M. Chalil to its Strategic Advisory Board

Medifocus Inc. announced that the company has established a Strategic Advisory Board (SAB) and has appointed Dr. Joseph M. Chalil, MD, MBA, FACHE, as one of the company's Strategic Business Advisors. Dr. Chalil is Associate Director, Health Science Executives of Boehringer Ingelheim. In addition to his responsibilities at Boehringer Ingelheim, Dr. Chalil is the Chairman of Global Clinical Research and Trial Network of the American Association of Physicians of Indian Origin (AAPI) and has served as Scientific Advisor to AAPI for the past five years.

Medifocus Inc. Announces Earnings Results for the Third Quarter and Nine Months Ended December 31, 2014

Medifocus Inc. announced earnings results for the third quarter and nine months ended December 31, 2014. For the three months ended December 31, 2014, sales were USD 895,973, representing a decrease of 30% from the same quarter of 2013, but an increase of 40% from the previous three months ended September 30, 2014 following the restructuring of its Prolieve® business earlier this fall. The net loss for the nine months ended December 31, 2014 is USD 4,093,013, compared to a net loss of USD 4,037,750 in the same period of the previous year. Sales from its Prolieve® Thermodilatation System reached USD 3,187,139 for the nine months ended December 31, 2014, a decrease of 14% from the same period of 2013. The net loss for the nine months ended December 31, 2014 is USD 4,093,013, compared to a net loss of USD 4,037,750 in the same period of the previous year.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MFS:CN C$0.05 CAD 0.00

MFS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Boston Scientific Corp $16.24 USD -0.29
Celsion Corp $1.97 USD -0.01
Eli Lilly & Co $80.32 USD -1.28
Urologix Inc $0.07 USD 0.0001
View Industry Companies
 

Industry Analysis

MFS

Industry Average

Valuation MFS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.5x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MEDIFOCUS INC, please visit www.medifocusinc.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.